Cargando…

Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study

The microbiome plays diverse roles in many diseases and can potentially contribute to cancer development. Breast cancer is the most commonly diagnosed cancer in women worldwide. Thus, we investigated whether the gut microbiota differs between patients with breast carcinoma and those with benign tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Peidong, Wang, Zhitang, Peng, Qingqin, Lian, Weibin, Chen, Debo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593289/
https://www.ncbi.nlm.nih.gov/pubmed/34795472
http://dx.doi.org/10.1177/11769343211057573
_version_ 1784599698351325184
author Yang, Peidong
Wang, Zhitang
Peng, Qingqin
Lian, Weibin
Chen, Debo
author_facet Yang, Peidong
Wang, Zhitang
Peng, Qingqin
Lian, Weibin
Chen, Debo
author_sort Yang, Peidong
collection PubMed
description The microbiome plays diverse roles in many diseases and can potentially contribute to cancer development. Breast cancer is the most commonly diagnosed cancer in women worldwide. Thus, we investigated whether the gut microbiota differs between patients with breast carcinoma and those with benign tumors. The DNA of the fecal microbiota community was detected by Illumina sequencing and the taxonomy of 16S rRNA genes. The α-diversity and β-diversity analyses were used to determine richness and evenness of the gut microbiota. Gene function prediction of the microbiota in patients with benign and malignant carcinoma was performed using PICRUSt. There was no significant difference in the α-diversity between patients with benign and malignant tumors (P = 3.15e(−1) for the Chao index and P = 3.1e(−1) for the ACE index). The microbiota composition was different between the 2 groups, although no statistical difference was observed in β-diversity. Of the 31 different genera compared between the 2 groups, level of only Citrobacter was significantly higher in the malignant tumor group than that in benign tumor group. The metabolic pathways of the gut microbiome in the malignant tumor group were significantly different from those in benign tumor group. Furthermore, the study establishes the distinct richness of the gut microbiome in patients with breast cancer with different clinicopathological factors, including ER, PR, Ki-67 level, Her2 status, and tumor grade. These findings suggest that the gut microbiome may be useful for the diagnosis and treatment of malignant breast carcinoma.
format Online
Article
Text
id pubmed-8593289
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85932892021-11-17 Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study Yang, Peidong Wang, Zhitang Peng, Qingqin Lian, Weibin Chen, Debo Evol Bioinform Online Metagenomics and the analysis of microbiomes The microbiome plays diverse roles in many diseases and can potentially contribute to cancer development. Breast cancer is the most commonly diagnosed cancer in women worldwide. Thus, we investigated whether the gut microbiota differs between patients with breast carcinoma and those with benign tumors. The DNA of the fecal microbiota community was detected by Illumina sequencing and the taxonomy of 16S rRNA genes. The α-diversity and β-diversity analyses were used to determine richness and evenness of the gut microbiota. Gene function prediction of the microbiota in patients with benign and malignant carcinoma was performed using PICRUSt. There was no significant difference in the α-diversity between patients with benign and malignant tumors (P = 3.15e(−1) for the Chao index and P = 3.1e(−1) for the ACE index). The microbiota composition was different between the 2 groups, although no statistical difference was observed in β-diversity. Of the 31 different genera compared between the 2 groups, level of only Citrobacter was significantly higher in the malignant tumor group than that in benign tumor group. The metabolic pathways of the gut microbiome in the malignant tumor group were significantly different from those in benign tumor group. Furthermore, the study establishes the distinct richness of the gut microbiome in patients with breast cancer with different clinicopathological factors, including ER, PR, Ki-67 level, Her2 status, and tumor grade. These findings suggest that the gut microbiome may be useful for the diagnosis and treatment of malignant breast carcinoma. SAGE Publications 2021-11-13 /pmc/articles/PMC8593289/ /pubmed/34795472 http://dx.doi.org/10.1177/11769343211057573 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Metagenomics and the analysis of microbiomes
Yang, Peidong
Wang, Zhitang
Peng, Qingqin
Lian, Weibin
Chen, Debo
Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study
title Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study
title_full Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study
title_fullStr Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study
title_full_unstemmed Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study
title_short Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study
title_sort comparison of the gut microbiota in patients with benign and malignant breast tumors: a pilot study
topic Metagenomics and the analysis of microbiomes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593289/
https://www.ncbi.nlm.nih.gov/pubmed/34795472
http://dx.doi.org/10.1177/11769343211057573
work_keys_str_mv AT yangpeidong comparisonofthegutmicrobiotainpatientswithbenignandmalignantbreasttumorsapilotstudy
AT wangzhitang comparisonofthegutmicrobiotainpatientswithbenignandmalignantbreasttumorsapilotstudy
AT pengqingqin comparisonofthegutmicrobiotainpatientswithbenignandmalignantbreasttumorsapilotstudy
AT lianweibin comparisonofthegutmicrobiotainpatientswithbenignandmalignantbreasttumorsapilotstudy
AT chendebo comparisonofthegutmicrobiotainpatientswithbenignandmalignantbreasttumorsapilotstudy